{"id":848521,"date":"2026-11-17T01:19:01","date_gmt":"2026-11-17T01:19:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=848521"},"modified":"2026-11-17T01:19:01","modified_gmt":"2026-11-17T01:19:01","slug":"veltis-sets-batch-coa-and-hplc-documentation-standard-for-peptides","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/veltis-sets-batch-coa-and-hplc-documentation-standard-for-peptides_848521.html","title":{"rendered":"Veltis Sets Batch COA and HPLC Documentation Standard for Peptides"},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>Veltis formalizes a batch-level chain of custody for research peptide COAs, pairing HPLC purity reports with mass-spectrometry identity checks before any compound ships to a research buyer in Mexico.<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Veltis publishes a batch-level COA and HPLC purity standard for research peptide buyers in Mexico, adding mass-spec identity checks to every listed lot.<\/div>\n<p style=\"text-align: justify;\"><strong>MEXICO CITY &#8211; 17 November, 2026 &#8211;<\/strong> <a rel=\"nofollow\" href=\"https:\/\/veltispeptides.mx\/\">Veltis<\/a>, an online supplier of research-use-only peptides serving laboratories and institutional buyers across Mexico, today published its documentation standard for batch-level Certificates of Analysis (COA) and HPLC purity reporting. The standard sets a three-part verification structure &mdash; lot-specific COA, HPLC purity by area, and mass-spectrometry identity confirmation &mdash; as the baseline for every SKU sold through the platform, not an optional add-on reserved for flagship compounds.<\/p>\n<p style=\"text-align: justify;\">Demand for research peptides in Mexico has grown faster than the documentation practices of the suppliers selling them. Buyers comparing presentations for compounds such as BPC-157, NAD+, GHK-Cu and GLP-class research peptides frequently receive a single purity number with no lot reference, no published COA, and no way to confirm identity independent of the seller&#8217;s own claim. Veltis is addressing that gap by tying every listed compound to a lot-traceable document trail, available to researchers before purchase rather than on request after.<\/p>\n<p style=\"text-align: justify;\">&#8220;Research buyers are not asking for marketing copy, they are asking for a lot number they can trace back to an actual analysis,&#8221; a Veltis spokesperson said. &#8220;A COA without a batch reference is not a COA, it is a PDF with a purity figure on it. We built the documentation standard around what a lab actually needs to verify before it logs a compound into its own records.&#8221;<\/p>\n<p style=\"text-align: justify;\">Batch-level COA as the baseline, not an add-on<\/p>\n<p style=\"text-align: justify;\">Under the new standard, every compound sold by Veltis carries a Certificate of Analysis tied to a specific manufacturing lot, not a generic specification sheet reused across batches. The COA states the lot number, the date of analysis, the purity result by HPLC peak area, and a mass-spectrometry identity confirmation distinguishing the intended peptide from structurally similar sequences. All documentation is published in a research-use-only (RUO) context, with no human-use claims, no dosage language, and no implied clinical application anywhere in the technical sheet or the COA itself.<\/p>\n<p style=\"text-align: justify;\">Reading HPLC purity without inflating it<\/p>\n<p style=\"text-align: justify;\">Purity by HPLC area is reported as the analytical method actually measures it &mdash; area percentage relative to detected peaks &mdash; rather than rounded or presented as a guaranteed minimum across all future lots. Secondary peaks, when present, are disclosed rather than omitted, and buyers are shown the same chromatographic read the lab used internally. Veltis treats a flagged secondary peak as a data point for the researcher&#8217;s own evaluation, not a defect to be hidden from the technical sheet.<\/p>\n<p style=\"text-align: justify;\">A supplier checklist institutional buyers can apply elsewhere<\/p>\n<p style=\"text-align: justify;\">The standard doubles as a checklist Veltis is publishing for researchers evaluating any peptide supplier, not just its own catalog: lot-specific traceability, a published COA accessible before purchase, mass-spectrometry identity confirmation independent of the purity figure, and RUO labeling with no human-use or dosage claims anywhere in the listing. Suppliers that cannot produce a batch-matched COA on request, according to Veltis, are not meeting the baseline a research buyer should require.<\/p>\n<p style=\"text-align: justify;\">&#8220;The checklist exists because we kept getting the same question from labs switching suppliers: how do we verify what we&#8217;re actually receiving,&#8221; a Veltis spokesperson said. &#8220;Publishing batch data and COA access as a standard, rather than a courtesy, is the only way to answer that consistently.&#8221;<\/p>\n<p style=\"text-align: justify;\"><strong>About Veltis<\/strong><\/p>\n<p style=\"text-align: justify;\">Veltis is an online supplier of research peptides &mdash; including BPC-157, NAD+, GHK-Cu and GLP-class compounds &mdash; serving research buyers in Mexico with technical sheets and batch-level Certificate of Analysis documentation for every listed compound. The company&#8217;s documentation standard requires lot-specific COA, HPLC purity reporting by peak area, and mass-spectrometry identity confirmation before a compound is listed for sale. All products and technical materials are published strictly in a research-use-only context, with no human-use claims, dosage guidance, or clinical application implied anywhere in the catalog. More information is available at veltispeptides.mx.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/veltispeptides.mx_197675.html\" rel=\"nofollow\">Veltis<\/a><br \/><strong>Contact Person:<\/strong> Press<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=veltis-sets-batch-coa-and-hplc-documentation-standard-for-peptides\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Address:<\/strong>Manuel Doblado 906, Monterrey Centro  <br \/><strong>City:<\/strong> Monterrey<br \/><strong>State:<\/strong> NL<br \/><strong>Country:<\/strong> Mexico<br \/><strong>Website:<\/strong> <a href=\"https:\/\/veltispeptides.mx\" target=\"_blank\" rel=\"nofollow\">https:\/\/veltispeptides.mx<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=veltis-sets-batch-coa-and-hplc-documentation-standard-for-peptides\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Veltis formalizes a batch-level chain of custody for research peptide COAs, pairing HPLC purity reports with mass-spectrometry identity checks before any compound ships to a research buyer in Mexico. Veltis publishes a batch-level COA and HPLC purity standard for research &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/veltis-sets-batch-coa-and-hplc-documentation-standard-for-peptides_848521.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420],"tags":[],"class_list":["post-848521","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/848521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=848521"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/848521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=848521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=848521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=848521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}